CV sales group future

Discussion in 'Merck' started by anonymous, Jan 5, 2016 at 9:56 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Nice try but no problems with the CV group
     

  2. anonymous

    anonymous Guest

    …yet.
     
  3. anonymous

    anonymous Guest

    Look at the organizational chart. CV is aligned with the "at risk" business units. Respiratory, EPBU. All on thin ice.
     
  4. anonymous

    anonymous Guest

    The ice has been melting rapidly, the CV group is gone by mid year. The group has nothing to offer.
     
  5. anonymous

    anonymous Guest

    Zontivity will bring in billions this year overshadowing our diabetes sales. This is a mega blockbuster my friends. RX's are being written left and right, manufacturing cannot keep up even with production lines running 24-7.
     
  6. anonymous

    anonymous Guest

    What a bunch of morons. At risk, eh? Show us that soup-tits
     
  7. anonymous

    anonymous Guest

    won't say too much but came out of meeting this morning...CV group actually looks pretty solid. don't let the naysayers get you down
     
  8. anonymous

    anonymous Guest

    Not to mention that we just hired a new DCO for the CV group

    Long live the CV team
     
  9. anonymous

    anonymous Guest

    :)
    Have the rep & CTL vacancies been filled? Heard there were some gaps to fill....
    Who is your new DCO?
     
  10. anonymous

    anonymous Guest

    Lady out of the home office named Liz. She has no experience in our markets but the point was made-we're not going anywhere soon.

    I believe she was a contract regional manager. Sure would have been nice to hire someone who knows our business but that would be way too much to ask.
     
  11. anonymous

    anonymous Guest

    you're right-we might be around for a while but the group as a whole won't be going anywhere.....its all about women..and being sure to hire nothing but women no matter what the qualifications are from others. First a new DCO without current market knowledge, then we hire two sreggin on the marketing team....same results will follow us...not much hope
     
  12. anonymous

    anonymous Guest

    YES, and we lose patent well before any of these so called cv pipeline drugs are in our bag. That leaves us with Z only which will be given to contract to sample by year end. Sounds like they are following the Dulera route of 2014. I am floating the resumes now ahead of the dreaded phone calls. My guess is October first and we are all done. Do not wait, they will disable us overnight like they did with allergy, opthalmics, psych and others. Managers will find out 24hrs before us, that is it! Once we get approval of Hep C tomorrow, they will have more reason to cut our ties. Get out, get out now, you have been warned. New DCO and others? Does not matter, they have done this before, hire only to fire months later.
     
  13. anonymous

    anonymous Guest

    True dat, but go where? All the pcsk-niner jobs have been filled at other co's. Look i know it is over this year but i am waiting for the package, even if there is no WARN $s. Even the dummy pc reps are leaving ahead of the storm, yikes.
     
  14. anonymous

    anonymous Guest

    Wrong on all accounts. There are no planned layoffs of the CV group this year in the works. If you're interested in the PCSK9's there are still jobs out there. Leave. Tired of the same guy posting in here trying to get everyone stirred up. Allergy was different You were at the end of promoting Singular with nothing left to sell. We are at the end-this year-with athero but at that time will probably have at least one other new drug to sell, and we will be awaiting our CTEP inhibitor. So, get your facts right dick ass. If ana doesn't get here, well, that will be another story that could change things. But for now, go eat and quit trying to rile everybody up for no reason. You're a clown. Go back to the circus where you belong.
     
  15. anonymous

    anonymous Guest

    Abbv troll above gonna get it.
     
  16. anonymous

    anonymous Guest

    First zetia generics on the market this december. Read MRK 10k form about vorapaxar. Merck will write it off as an intangible asset loss due to poor performance in the states and EU. All our bag drugs done, NO NEW products before then. Run Gomer run.
     
  17. anonymous

    anonymous Guest

    Okay douche bag. Where do you get your information? Lets see you cut and paste it so we can all see it. What's that? You don't know who to cut and paste? That figures
     
  18. anonymous

    anonymous Guest


    This is how easy it is to expose the naysayers and people who make things up to worry others. Just ask them to prove where things are like the MRK 10k for this poster cites. Its a lot like the so-called lay offs they spout off about. Very rarely does it happen. Now, EAT.
     
  19. anonymous

    anonymous Guest

    The decision will be made today on the future of the CV group. Heavy support for dissolution and replacement by contract personnel.
     
  20. anonymous

    anonymous Guest

    Yeah right prick ass. We have a new DCO, we're hiring new CTL's, and we're back-filling vacated territories. Go back to your cave dick lick.